Movatterモバイル変換


[0]ホーム

URL:


US20040058982A1 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions
Download PDF

Info

Publication number
US20040058982A1
US20040058982A1US10/422,848US42284803AUS2004058982A1US 20040058982 A1US20040058982 A1US 20040058982A1US 42284803 AUS42284803 AUS 42284803AUS 2004058982 A1US2004058982 A1US 2004058982A1
Authority
US
United States
Prior art keywords
compounds
citrus
alkyl
water
pass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/422,848
Inventor
James Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioavailability Systems LLC
Original Assignee
Bioavailability Systems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/251,467external-prioritypatent/US6248776B1/en
Application filed by Bioavailability Systems LLCfiledCriticalBioavailability Systems LLC
Priority to US10/422,848priorityCriticalpatent/US20040058982A1/en
Publication of US20040058982A1publicationCriticalpatent/US20040058982A1/en
Priority to US11/081,024prioritypatent/US7230027B2/en
Priority to US11/696,198prioritypatent/US7576123B2/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

Compositions, methods, etc. for addressing the first-pass effect.

Description

Claims (2)

US10/422,8481997-08-262003-04-25Pharmaceutical compositionsAbandonedUS20040058982A1 (en)

Priority Applications (3)

Application NumberPriority DateFiling DateTitle
US10/422,848US20040058982A1 (en)1999-02-172003-04-25Pharmaceutical compositions
US11/081,024US7230027B2 (en)1997-08-262005-03-16Anti-first-pass effect compounds
US11/696,198US7576123B2 (en)1997-08-262007-04-04Anti-first-pass effect compounds

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US09/251,467US6248776B1 (en)1997-08-261999-02-17Anti-first-pass effect compounds
US09/793,416US6476066B1 (en)1997-08-262001-02-27Anti-first-pass effect compounds
US10/422,848US20040058982A1 (en)1999-02-172003-04-25Pharmaceutical compositions

Related Parent Applications (2)

Application NumberTitlePriority DateFiling Date
US09/251,467DivisionUS6248776B1 (en)1997-08-261999-02-17Anti-first-pass effect compounds
US09/793,416Continuation-In-PartUS6476066B1 (en)1997-08-262001-02-27Anti-first-pass effect compounds

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US11/081,024ContinuationUS7230027B2 (en)1997-08-262005-03-16Anti-first-pass effect compounds

Publications (1)

Publication NumberPublication Date
US20040058982A1true US20040058982A1 (en)2004-03-25

Family

ID=29739175

Family Applications (3)

Application NumberTitlePriority DateFiling Date
US10/422,848AbandonedUS20040058982A1 (en)1997-08-262003-04-25Pharmaceutical compositions
US11/081,024Expired - Fee RelatedUS7230027B2 (en)1997-08-262005-03-16Anti-first-pass effect compounds
US11/696,198Expired - Fee RelatedUS7576123B2 (en)1997-08-262007-04-04Anti-first-pass effect compounds

Family Applications After (2)

Application NumberTitlePriority DateFiling Date
US11/081,024Expired - Fee RelatedUS7230027B2 (en)1997-08-262005-03-16Anti-first-pass effect compounds
US11/696,198Expired - Fee RelatedUS7576123B2 (en)1997-08-262007-04-04Anti-first-pass effect compounds

Country Status (1)

CountryLink
US (3)US20040058982A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20050171191A1 (en)*1997-08-262005-08-04Bioavailability Systems, LlcAnti-first-pass effect compounds
US20070060510A1 (en)*2003-04-182007-03-15Enanta Pharmaceuticals, Inc.Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US20070179167A1 (en)*2005-08-262007-08-02Cottrell Kevin MInhibitors of serine proteases
US20070244188A1 (en)*1997-08-262007-10-18Bioavailability Systems, LlcAnti-first-pass effect compounds
US20070287664A1 (en)*2006-03-232007-12-13Schering CorporationCombinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
US20080267915A1 (en)*2004-10-012008-10-30Vertex PharmaceuticalsHcv Ns3-Ns4a Protease Inhibition
US20100137583A1 (en)*2000-08-312010-06-03Robert Edward BabinePeptidomimetic protease inhibitors
US20100144608A1 (en)*2008-09-112010-06-10Yiyin KuMacrocyclic hepatitis C serine protease inhibitors
WO2010093843A2 (en)2009-02-122010-08-19Vertex Pharmaceuticals IncorporatedHcv combination therapies
US20100272681A1 (en)*2007-02-272010-10-28Vertex Pharmaceuticals IncorporatedInhibitors of Serine Proteases
US20110009424A1 (en)*2007-08-302011-01-13Vertex Pharmaceuticals IncorporatedCo-Crystals and Pharmaceutical Compositions Comprising the same
US20110059987A1 (en)*2007-02-272011-03-10Vertex Pharmaceuticals IncorporatedCo-Crystals and Pharmaceutical Compositions Comprising the Same
US7964624B1 (en)2005-08-262011-06-21Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US20110171175A1 (en)*2005-08-022011-07-14Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
WO2011094489A1 (en)2010-01-292011-08-04Vertex Pharmaceuticals IncorporatedTherapies for treating hepatitis c virus infection
US20110207660A1 (en)*2008-08-072011-08-25Schering CorporationPharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US8039475B2 (en)2006-02-272011-10-18Vertex Pharmaceuticals IncorporatedCo-crystals and pharmaceutical compositions comprising the same
WO2011156545A1 (en)2010-06-092011-12-15Vertex Pharmaceuticals IncorporatedViral dynamic model for hcv combination therapy
WO2012009503A1 (en)2010-07-142012-01-19Vertex Pharmaceuticals IncorporatedPalatable pharmaceutical composition comprising vx-950
US8217048B2 (en)2003-09-052012-07-10Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2012109646A1 (en)2011-02-112012-08-16Vertex Pharmaceuticals IncorporatedTreatment of hcv in hiv infection patients
US8247532B2 (en)2006-03-162012-08-21Vertex Pharmaceuticals IncorporatedDeuterated hepatitis C protease inhibitors
EP2500021A1 (en)2004-10-292012-09-19Vertex Pharmaceuticals Inc.Therapeutic uses of VX-950
US8314141B2 (en)1996-10-182012-11-20Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly hepatitis C virus NS3 protease
WO2013116339A1 (en)2012-01-312013-08-08Vertex Pharmaceuticals IncorporatedHigh potency formulations of vx-950
US8937041B2 (en)2010-12-302015-01-20Abbvie, Inc.Macrocyclic hepatitis C serine protease inhibitors
US8951964B2 (en)2010-12-302015-02-10Abbvie Inc.Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US9333204B2 (en)2014-01-032016-05-10Abbvie Inc.Solid antiviral dosage forms
US10201584B1 (en)2011-05-172019-02-12Abbvie Inc.Compositions and methods for treating HCV
CN111650293A (en)*2020-04-242020-09-11广州白云山奇星药业有限公司Quality detection method of Jindan pill
US11919901B2 (en)2021-05-142024-03-05Syndax Pharmaceuticals, Inc.Inhibitors of the menin-MLL interaction
WO2024223797A1 (en)2023-04-282024-10-31Institut National de la Santé et de la Recherche MédicaleUse of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections
US12312359B2 (en)2016-06-102025-05-27Vitae Pharmaceuticals, LlcInhibitors of the menin-MLL interaction

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
RU2010113982A (en)*2007-09-112011-10-20Мондобайотек Лабораториз Аг (Li) APPLICATION OF A PEPTIDE AS A THERAPEUTIC

Citations (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6054477A (en)*1997-08-262000-04-25Bioavailability Systems, LlcAnti-first-pass effect compounds
US6248776B1 (en)*1997-08-262001-06-19Bioavailability Systems, L.L.C.Anti-first-pass effect compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE1084733B (en)1958-08-071960-07-07Bayer Ag Process for the production of bicyclic acetals
JPS57179186A (en)1981-04-301982-11-04Toagosei Chem Ind Co Ltd2-methylene-7,8-benzo-1,4,6-trioxaspiro(4.5)decene-9,10
JPH063540B2 (en)1985-09-281994-01-12コニカ株式会社 Method of forming photographic image
JPS6280642A (en)1985-10-041987-04-14Konishiroku Photo Ind Co LtdSilver halide photographic sensitive material
JP2566393B2 (en)1986-01-271996-12-25コニカ株式会社 Silver halide photographic material
JPS62173457A (en)1986-01-271987-07-30Konishiroku Photo Ind Co LtdSilver halide photographic sensitive material
DE3834988A1 (en)*1988-10-141990-04-19Sueddeutsche Kalkstickstoff METHOD FOR REMOVING TERPENES FROM ETHERIC OILS
US5968942A (en)*1992-08-251999-10-19G. D. Searle & Co.α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5362714A (en)*1993-06-291994-11-08The Coca-Cola CompanyProcess for dewaxing citrus oils
WO1995002589A1 (en)1993-07-161995-01-26Japan Tobacco Inc.Novel chroman compound, intermediate thereof, and medicinal use thereof
US5820915A (en)*1996-06-271998-10-13Bioavailability Systems, L.L.C.Method for the preparation of a first-pass effective citrus-derived substance and product thereof
US6124477A (en)*1996-06-272000-09-26Bioavailability Systems, LlcAnti-first-pass effect compounds
US5817354A (en)1996-08-221998-10-06Sepragen CorporationHigh throughput debittering
US6613918B1 (en)*2000-10-202003-09-02Bioavailability Systems, LlcSynthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
US5990154A (en)*1997-05-301999-11-23Bioavailability Systems, L.L.C.Anti-first-pass effect compounds and citrus extract
US20040058982A1 (en)*1999-02-172004-03-25Bioavailability System, LlcPharmaceutical compositions
US5993887A (en)*1998-06-291999-11-30Bioavailability Systems, L.L.C.Safe citrus juice and process for preparation
US20070287664A1 (en)*2006-03-232007-12-13Schering CorporationCombinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6054477A (en)*1997-08-262000-04-25Bioavailability Systems, LlcAnti-first-pass effect compounds
US6248776B1 (en)*1997-08-262001-06-19Bioavailability Systems, L.L.C.Anti-first-pass effect compounds
US6476066B1 (en)*1997-08-262002-11-05Bioavailability Systems, L.L.C.Anti-first-pass effect compounds

Cited By (58)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US8314141B2 (en)1996-10-182012-11-20Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US7576123B2 (en)1997-08-262009-08-18Bioavailability Systems, L.L.C.Anti-first-pass effect compounds
US20050171191A1 (en)*1997-08-262005-08-04Bioavailability Systems, LlcAnti-first-pass effect compounds
US20070244188A1 (en)*1997-08-262007-10-18Bioavailability Systems, LlcAnti-first-pass effect compounds
US7576124B2 (en)1997-08-262009-08-18Bioavailability Systems, L.L.C.Anti-first-pass effect compounds
US20080039520A1 (en)*1997-08-262008-02-14Bioavailability Systems, LlcAnti-first-pass effect compounds
US8529882B2 (en)2000-08-312013-09-10Vertex Pharmaceuticals IncorporatedPeptidomimetic protease inhibitors
US20100137583A1 (en)*2000-08-312010-06-03Robert Edward BabinePeptidomimetic protease inhibitors
US8252923B2 (en)2000-08-312012-08-28Vertex Pharmaceuticals IncorporatedPeptidomimetic protease inhibitors
US7820671B2 (en)2000-08-312010-10-26Vertex Pharmaceuticals IncorporatedPeptidomimetic protease inhibitors
US7368452B2 (en)2003-04-182008-05-06Enanta Pharmaceuticals, Inc.Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US20070060510A1 (en)*2003-04-182007-03-15Enanta Pharmaceuticals, Inc.Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US8217048B2 (en)2003-09-052012-07-10Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20080267915A1 (en)*2004-10-012008-10-30Vertex PharmaceuticalsHcv Ns3-Ns4a Protease Inhibition
EP2374464A2 (en)2004-10-012011-10-12Vertex Pharmaceuticals IncorporatedHCV N3S-NS4A protease inhibition
US20110059886A1 (en)*2004-10-012011-03-10Vertex Pharmaceuticals IncorporatedHCV NS3-NS4A Protease Inhibition
EP2500021A1 (en)2004-10-292012-09-19Vertex Pharmaceuticals Inc.Therapeutic uses of VX-950
US20110171175A1 (en)*2005-08-022011-07-14Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US8372873B2 (en)2005-08-262013-02-12Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US7964624B1 (en)2005-08-262011-06-21Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US20110165120A1 (en)*2005-08-262011-07-07Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US7985762B2 (en)2005-08-262011-07-26Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US20110182856A1 (en)*2005-08-262011-07-28Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US8440706B2 (en)2005-08-262013-05-14Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US20070179167A1 (en)*2005-08-262007-08-02Cottrell Kevin MInhibitors of serine proteases
US8372846B2 (en)2006-02-272013-02-12Vertex Pharmaceuticals IncorporatedCo-crystals and pharmaceutical compositions comprising the same
US8039475B2 (en)2006-02-272011-10-18Vertex Pharmaceuticals IncorporatedCo-crystals and pharmaceutical compositions comprising the same
US8247532B2 (en)2006-03-162012-08-21Vertex Pharmaceuticals IncorporatedDeuterated hepatitis C protease inhibitors
US20100291034A1 (en)*2006-03-232010-11-18Schering CorporationCombinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
US20070287664A1 (en)*2006-03-232007-12-13Schering CorporationCombinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto
US8575208B2 (en)2007-02-272013-11-05Vertex Pharmaceuticals IncorporatedInhibitors of serine proteases
US8759353B2 (en)2007-02-272014-06-24Vertex Pharmaceuticals IncorporatedCo-crystals and pharmaceutical compositions comprising the same
US20100272681A1 (en)*2007-02-272010-10-28Vertex Pharmaceuticals IncorporatedInhibitors of Serine Proteases
US20110059987A1 (en)*2007-02-272011-03-10Vertex Pharmaceuticals IncorporatedCo-Crystals and Pharmaceutical Compositions Comprising the Same
US20110009424A1 (en)*2007-08-302011-01-13Vertex Pharmaceuticals IncorporatedCo-Crystals and Pharmaceutical Compositions Comprising the same
US8492546B2 (en)2007-08-302013-07-23Vertex Pharmaceuticals IncorporatedCo-crystals and pharmaceutical compositions comprising the same
US20110207660A1 (en)*2008-08-072011-08-25Schering CorporationPharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US20100144608A1 (en)*2008-09-112010-06-10Yiyin KuMacrocyclic hepatitis C serine protease inhibitors
US9309279B2 (en)2008-09-112016-04-12Abbvie Inc.Macrocyclic hepatitis C serine protease inhibitors
US8420596B2 (en)2008-09-112013-04-16Abbott LaboratoriesMacrocyclic hepatitis C serine protease inhibitors
US8642538B2 (en)2008-09-112014-02-04Abbvie, Inc.Macrocyclic hepatitis C serine protease inhibitors
WO2010093843A2 (en)2009-02-122010-08-19Vertex Pharmaceuticals IncorporatedHcv combination therapies
WO2011094489A1 (en)2010-01-292011-08-04Vertex Pharmaceuticals IncorporatedTherapies for treating hepatitis c virus infection
WO2011156545A1 (en)2010-06-092011-12-15Vertex Pharmaceuticals IncorporatedViral dynamic model for hcv combination therapy
WO2012009503A1 (en)2010-07-142012-01-19Vertex Pharmaceuticals IncorporatedPalatable pharmaceutical composition comprising vx-950
US8951964B2 (en)2010-12-302015-02-10Abbvie Inc.Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US8937041B2 (en)2010-12-302015-01-20Abbvie, Inc.Macrocyclic hepatitis C serine protease inhibitors
WO2012109646A1 (en)2011-02-112012-08-16Vertex Pharmaceuticals IncorporatedTreatment of hcv in hiv infection patients
US10201584B1 (en)2011-05-172019-02-12Abbvie Inc.Compositions and methods for treating HCV
US10201541B1 (en)2011-05-172019-02-12Abbvie Inc.Compositions and methods for treating HCV
WO2013116339A1 (en)2012-01-312013-08-08Vertex Pharmaceuticals IncorporatedHigh potency formulations of vx-950
US9333204B2 (en)2014-01-032016-05-10Abbvie Inc.Solid antiviral dosage forms
US9744170B2 (en)2014-01-032017-08-29Abbvie Inc.Solid antiviral dosage forms
US10105365B2 (en)2014-01-032018-10-23Abbvie Inc.Solid antiviral dosage forms
US12312359B2 (en)2016-06-102025-05-27Vitae Pharmaceuticals, LlcInhibitors of the menin-MLL interaction
CN111650293A (en)*2020-04-242020-09-11广州白云山奇星药业有限公司Quality detection method of Jindan pill
US11919901B2 (en)2021-05-142024-03-05Syndax Pharmaceuticals, Inc.Inhibitors of the menin-MLL interaction
WO2024223797A1 (en)2023-04-282024-10-31Institut National de la Santé et de la Recherche MédicaleUse of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Also Published As

Publication numberPublication date
US20070244188A1 (en)2007-10-18
US20050214366A1 (en)2005-09-29
US7576123B2 (en)2009-08-18
US7230027B2 (en)2007-06-12

Similar Documents

PublicationPublication DateTitle
US7576123B2 (en)Anti-first-pass effect compounds
US7576124B2 (en)Anti-first-pass effect compounds
US7514572B2 (en)Anti-first-pass effect compounds
JP2023520347A (en) Pharmaceutical composition for prevention or treatment of disease caused by SARS-CoV-2
US5962044A (en)Citrus extract
US6124477A (en)Anti-first-pass effect compounds
EP2407160A1 (en)Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as active ingredient
US5990154A (en)Anti-first-pass effect compounds and citrus extract
EP1019042B1 (en)Anti-first-pass effect compounds
CA2615641C (en)A composition comprising an extract of tiarella polyphylla and tiarellic acid isolated therefrom having antiinflammatory, antiallergic and antiasthmatic activity
KR20060014006A (en) Processing Method of Ginseng Extract with High Content of △ 20-Ginsenoside and Use of Processed Ginseng Extract
WO1998024316A1 (en)Anti-first-pass effect compounds and citrus extract
MXPA00001714A (en)Anti-first-pass effect compounds

Legal Events

DateCodeTitleDescription
STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp